Power and Microwave
Hybrid power amplifiers, traveling wave tubes & power tubes
Read MoreDigital Vision
Custom image tubes, infrared cameras & specialized camera night vision cores
Read MoreNight Vision
Night vision goggles & image intensifier tubes
Read MoreAdvanced Development
Imagining capabilities with novel technologies & cutting edge R&D
Read MorePD-PRO-Q Panoramic Night Vision Goggle
PD-PRO-Q is the most compact and lightest panoramic
goggle on the market today designed for Tier 1 teams.
The expanded
field-of-view (FOV) combined with our HypersenseTM 4G tube
technology also expands the detection range, allowing the
operator to see laser illuminators not visible to standard
military issue night vision goggles without the need for
additional digital or thermal clip-on devices.
Spectral sensitivity: Below 400nm to above 1,000 nm
Weight: < 28 oz. (< 800 grams)
Horizontal field of view: 104°
The next evolution in night vision
MEET THE PD-PRO SERIES
Versatile Imaging Solutions
Innovative digitial imaging technologies that support a variety of applications from security and surveillance to research.
DIGITAL VISION
Powerful SWaP Optimized MPMs
Microwave Power Modules that are smaller, lighter and consume less power while still providing the best performance possible in electronic warfare applications.
POWER AND MICROWAVE
News & Information
Title search: ✖
|
Exosens makes first US investment in night vision production capacity to address growing demand and benefit from new opportunities
March 3, 2025
The global night vision market is benefiting from growing demand, driven by increasing defense budgets and the need for armies worldwide to enhance their night fighting capabilities. The return of high-density combat has underscored the critical importance of night operation abilities as a key tactical advantage. NATO and Tier-1 allies continued to ramp up their procurement of night vision systems in 2024, though they are still far from reaching the targeted equipment rate.
With decades of expertise, Photonis, a brand of Exosens, offers image intensifier tubes, the engine of night vision devices, which improve soldiers’ tactical situational awareness, agility and mobility, as well as their targeting and driving capabilities, in the darkest of nights.
In order to meet increasing night vision demand, Exosens invests €20m to expand its production capacity not only in Europe but also in the US with, for the first time, a new production plant in the US, underscoring additional market opportunities with locally produced "Made in America" image intensifier tubes.
This new installation will take place in Sturbridge (Massachusetts), where the group has already its Photonis Scientific Inc subsidiary. Exosens will take advantage of the support and synergies available within the group to optimize the time setup for the manufacturing of the image intensifier tubes, which is expected to begin in early 2027.
“We are pleased to announce a new investment in our capacity on the US ground, which represents a major step in our strategy. Expansion into the US market presents a significant opportunity to strengthen our position as a global leader in image intensifier tubes. This new capacity will also enable us to meet customers' demand for large-volume, high-performance products manufactured in the US.” said Exosens CEO, Jérôme Cerisier
Media relations:
Brunswick Group – exosens@brunswickgroup.com
Laetitia Quignon, + 33 6 83 17 89 13
Nicolas Buffenoir, + 33 6 31 89 36 78
Forward-looking statements
Certain information included in this press release are not historical facts but are forward-looking statements. These forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Exosens operates, and involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to be materially different from the forward-looking statements included in this press release. These risks include those described in chapter 3 of Exosens’ registration document approved by the French Autorité des marchés financiers under number I.24-0010 on 22 May 2024.
|
